|
Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma
STATEMENT OF NEED
An estimated 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Characterized by clonal proliferation of malignant plasma cells in the bone marrow, multiple myeloma is associated with anemia, renal insufficiency, bone destruction, and hypercalcemia, all of which significantly impact patients’ quality of life. The development of novel therapies and combinations in recent years, inclu... |
|
|
Skin Cancer Education for Primary Care
This comprehensive course on skin cancer will help you improve your ability to diagnose and manage skin lesions, the most common of all cancers.
Outcome Objectives:
As a result of completing this activity, the participant will be better able to:
- Understand the biology of ultraviolet radiation and methods to protect the skin.
- Demonstrate increased proficiency in the management of potentially malignant skin lesions.
- Make early diagnoses of skin cancers, particularly melanoma.... |
|
|
The Role of the Clinical Pharmacist in the Management of Multiple Myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy in the United States and is characterized by monoclonal proliferation of malignant plasma cells that accumulate within the bone marrow. The incidence of MM has increased in recent years, in part due to the revised definition of symptomatic MM from the International Myeloma Working Group in 2014. The National Cancer Institute estimated a total of 34,470 new cases in 2022, with 12,640 deaths. Despite significant advancements ... |
|
|
Clinical Competence in Breast Imaging, Interventions and Management
Clinical Competence in Breast Imaging, Interventions and Management provides a complete tutorial in all modalities, diagnostic strategies and interventional considerations encountered in the modern breast imaging practice. Its fifty cases allow the participant to explore a wide range of benign and malignant disease, with special focus placed on the variety of presentations and patterns of enhancement observed on mammogram, ultrasound, MRI and tomosynthesis. This activity also expounds on the... |
|
|
Applying Evolving Targeted Therapy in Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a biologically heterogeneous hematologic malignant neoplasm with a 5-year survival rate of 30%. Hematologist, Brian Jonas, MD, PhD, UC Davis Comprehensive Cancer, discusses standard induction, consolidation, and maintenance therapy, as well as factors to consider in individualizing intensive therapy in fit and unfit patients. Dr. Jonas presents safety and efficacy data for approved and emerging therapies that target BCL-2, FLT-3 ITD/TDK, CD33, CD47, IDH1/2, E-se... |
|
|
LET'S TALK: Tackling Complex Issues Regarding SM-AHN Management A Monday Morning Joe Online Educational Activity
Systemic mastocytosis (SM) is a group of rare disorders characterized by the accumulation of mast cells in internal tissues and organs. The pathogenesis of SM is linked to a characteristic exon 17 D816V mutation of the KIT gene. Systemic mastocytosis with associated hematologic neoplasms (SM-AHN) is an advanced subtype of SM that is associated with a shortened median survival time. Recent advances in the SM therapeutic landscape have led to the development of KIT-targeted treatment options; ho... |
|
|
Clinical Competence in Breast MR, Volume 2
Clinical Competence in Breast MR, volume 2 meets ACR CME requirements for facility accreditation in Breast MR. Reaccredited in 2023, the program contains 100 comprehensive Breast MR cases. The cases include detailed patient histories, a robust assortment of images, dynamic sequences and teaching points from a nationally renowned faculty. This review explores the many indications for malignant and benign disease, featuring nodules, tumors and patterns of enhancement encountered in every day... |
|